A US study has found that only 2% of high-risk infants developed peanut allergy after introduction of peanuts into their diet. The results support other studies showing low rates of new allergies after early introduction of peanut but demonstrate the need for extra guidance, reassurance and support, especially if others in the family have a peanut allergy.
Read more
52-year-old Lorraine Madgett, who died after choking on peanut butter and toast at a care home in north Norfolk may have had a peanut allergy, a court has heard. An inquest into Lorraine’s death has been scheduled for July 31st 2024.
Read more
Do you have an allergy to either peanuts, seafood, or bee/wasp stings, that requires use of an EpiPen? The University of Manchester is looking for a member of the public who can give a patient’s perspective of allergies to a group of master’s students who are studying the immune system.
Read more
Like many of you, we were disappointed when we saw the much anticipated Uber Eats advert due to be screened in front of millions at this weekend’s Super Bowl.
Read more
Dietitian Tanya Wright shares her advice for making delicious pancakes on Pancake Day, whether you or your family are allergic to milk, wheat or eggs.
Read more
2023 was a year of great progress in research, with new treatments, prevention strategies and improvements in diagnostic tests on the horizon. We look back at some of the highlights.
Read more
It’s one of the most romantic days of the year, but Valentine’s Day can present challenges for people with serious allergies. Allergens can find their way into foods, places and situations, such as chocolates, restaurants and romantic encounters, making it difficult to relax if you have a serious allergy. See our suggestions for keeping date night free from allergic reactions.
Read more
ALK have announced that it has completed the first part of its phase 1 clinical trial known as ALLIANCE for a new immunotherapy tablet for peanut allergy. The trial will now progress into its second part, expected to complete later in 2024.
Read more
Novartis, the Swiss pharmaceutical company, has halted its phase 3 study of the biologic drug ligelizumab for peanut allergy this January, but plans to launch a new study at a different dose. If approved, the study will begin in Autumn 2024.
Read more